Notably, SMIM30 expression levels are associated with low survival rates in HCC patients, suggesting that SMIM30 may be a new therapeutic target for HCC and a novel marker for the diagnosis and prognosis of HCC. Here, SMIM30 is linked to hepatocellular carcinoma.